NASDAQ: OKYOOkyo Pharma Ltd Stock
$1.44+0.07 (+5.11%)
Updated Jul 21, 2026
OKYO Price
$1.44
Fair Value Price
$0.04
Market Cap
$75.57M
52 Week Low
$1.34
52 Week High
$3.35
P/E
-6x
P/B
6.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.7
Operating Cash Flow
-$6M
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OKYO Overview
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OKYO's potential to beat the market
- OKYO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OKYO
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $254.22 | A | |
| $11.20 | A | |
| $8.78 | A |
Be the first to know about important OKYO news, forecast changes, insider trades & much more!
OKYO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OKYO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OKYO ($1.44) is overvalued by 3,542.96% relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OKYO ($1.44) is not significantly undervalued (3,542.96%) relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OKYO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OKYO due diligence checks available for Premium users.
Valuation
OKYO fair value
Fair Value of OKYO stock based on Discounted Cash Flow (DCF)
Price
$1.44
Fair Value
$0.04
Overvalued by
3,542.96%
OKYO ($1.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OKYO ($1.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OKYO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OKYO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6x
Industry
21.35x
Market
12.07x
OKYO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.13x
Industry
5.42x
OKYO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OKYO's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
OKYO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$21.0M
Liabilities
$8.6M
Debt to equity
0.7
OKYO's short-term assets ($20.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OKYO's short-term assets ($20.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OKYO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OKYO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
OKYO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OKYO vs Biotech Stocks
Okyo Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.